Literature DB >> 18555106

The use of oxygenated perfluorocarbonic emulsion for initial in situ kidney perfusion.

O N Reznik1, S F Bagnenko, I V Loginov, V A Iljina, A N Ananyev, Y G Moysyuk.   

Abstract

Protection of grafts from ischemia-reperfusion injury (IRI) remains an important problem, especially in uncontrolled donors. This study was performed to define the effect of oxygenated perfluorocarbonic emulsion for initial in situ conservation. One hundred and seventeen kidney grafts were procured from 2003 until 2006 from sixty one DCDs of Maastricht II and IV category. Control group donors (HTK group, n = 31) were operated using the traditional rapid laparotomy. The study group donors (Perftoran group, n = 30) had femoral access obtained in the ICU with initial perfusion by perfluorocarbonic PFG emulsion. The recipients were divided according to the type of the initial perfusion of the kidneys into a control group (n = 59) whose kidneys were initially perfused using HTK solution, and a study group (n = 58), who received kidneys preserved with initial perfusion in situ using oxygenated Perftoran. The rate of delayed graft function was significantly (up to 30%) higher among the control group. In the study group, the rate of immediate function was twice as high as that in the control group. By postoperative day 21, the level of serum creatinine in the study group decreased twice that of the control group. Initial perfusion with oxygenated perfluorocarbonic emulsion in situ may minimize a IRI of DCD kidneys.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555106     DOI: 10.1016/j.transproceed.2008.03.053

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Perfluoroalkyl substances are inversely associated with coronary heart disease in adults with diabetes.

Authors:  Kyoko Honda-Kohmo; Robert Hutcheson; Kim E Innes; Baqiyyah N Conway
Journal:  J Diabetes Complications       Date:  2019-02-20       Impact factor: 2.852

2.  Transient hyperoxic reoxygenation reduces cytochrome C oxidase activity by increasing superoxide dismutase and nitric oxide.

Authors:  Amina Arab; Jin Wang; Kathrin Bausch; Katharina von Schmädel; Christoph Bode; Christoph Hehrlein
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

3.  Perfluoroalkyl substances and beta cell deficient diabetes.

Authors:  Baqiyyah Conway; Karen E Innes; Dustin Long
Journal:  J Diabetes Complications       Date:  2016-05-04       Impact factor: 2.852

4.  Cerebral Microvascular and Systemic Effects Following Intravenous Administration of the Perfluorocarbon Emulsion Perftoran.

Authors:  Rania Abutarboush; Biswajit K Saha; Saad H Mullah; Francoise G Arnaud; Ashraful Haque; Chioma Aligbe; Georgina Pappas; Charles R Auker; Richard M McCarron; Paula F Moon-Massat; Anke H Scultetus
Journal:  J Funct Biomater       Date:  2016-11-18

5.  Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes.

Authors:  Baqiyyah N Conway; Ashley N Badders; Tina Costacou; John M Arthur; Kim E Innes
Journal:  Diabetes Metab Syndr Obes       Date:  2018-11-15       Impact factor: 3.168

6.  Perfluoroalkyl substances and likelihood of stroke in persons with and without diabetes.

Authors:  Robert Hutcheson; Kim Innes; Baqiyyah Conway
Journal:  Diab Vasc Dis Res       Date:  2019-12-16       Impact factor: 3.291

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.